|
Angle PLC - Surrey, England-based medical diagnostics company - Establishes partnership with MidLantic Urology to evaluate the use of its Parasortix system in prostate cancer clinical studies. MidLantic is as an affiliate of special urology services provider Solaris, which has over 500 clinical urology providers across 179 locations in the US, with over 729,000 annual patients. Angle hopes the collaboration will ‘enable potential sales’ to Solaris' patient base. The first study is expected to start in the third quarter of 2022, with results to be available in 2023.
‘We are delighted that Solaris and MidLantic Urology have agreed to work with Angle on clinical studies in prostate cancer, which build on prior work done by Barts Cancer Institute and demonstrates the power of our leveraged research approach,’ says Founder & Chief Executive Andrew Newland.
Current stock price: 145.63 pence
12-month change: up 5.6%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
